Document is current
Any future updates will be listed below
-
Authors
Overeem, Lucas Hendrik https://orcid.org/0000-0003-2057-7184
Ulrich, Marlene
Fitzek, Mira Pauline https://orcid.org/0000-0003-0299-4830
Lange, Kristin Sophie https://orcid.org/0000-0002-8056-8514
Hong, Ja Bin https://orcid.org/0009-0002-1541-0291
Reuter, Uwe https://orcid.org/0000-0002-8527-0725
Raffaelli, Bianca https://orcid.org/0000-0001-9758-1494
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 14 October 2024
Accepted: 12 December 2024
First Online: 9 January 2025
Declarations
:
: This study was approved by the Charité – Universitätsmedizin Berlin ethical committee (EA4/246/23). Due to the retrospective nature of this study, written informed consent from enrolled patients was not required under local regulations.
: Not applicable.
: LHO has nothing to declare. MU has nothing to declare. MF reports personal fees from Novartis and Teva. JBH has nothing to declare. KSL reports personal fees from Teva and Acticor Biotech. UR reports personal fees from Amgen, Allergan, Abbvie, Lilly, Lundbeck, Novartis, electroCore, Medscape, StreaMedUp, and Teva, and research funding from Novartis. BR reports research grants from Novartis, Lundbeck, German Migraine and Headache Society (DMKG), German Research Foundation (DFG) and Else Kröner-Fresenius-Stiftung, and personal fees from Abbvie/Allergan, Eli Lilly, Lundbeck, Novartis, Perfood and Teva.
